Trials / Terminated
TerminatedNCT00750555
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Phase II Study of Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Geisinger Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib | 150 mg per day orally until disease progression occurs, up to a maximum of 12 months |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2008-09-10
- Last updated
- 2019-02-26
- Results posted
- 2019-02-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00750555. Inclusion in this directory is not an endorsement.